Supreme Court's gene patent decision celebrated by research labs

Research labs celebrate gene patent decision 01:30

(CBS News) There was a groundbreaking ruling at the U.S. Supreme Court Thursday. The justices ruled unanimously that biotech companies may not patent human genes. However, genes in the lab may be patented.

In research labs Thursday, they celebrated the court's decision.

"It's a great day for genomic liberty," said Christopher Mason, a geneticist at Weill Cornell Medical College in New York.

Supreme Court says human genes cannot be patented
Biotech loves Supreme Court ruling on gene patents
Supreme Court's gene patent ruling could boost patient care

Mason was an expert witness in the case. He said the patents restricted scientists' ability to do important research.

(Watch CBS News chief legal correspondent Jan Crawford break down the case at left)

"If you just had these patents, you'd have to hold your hands over different parts of these and say, 'I can't look here. I can't look here, or these are prevented,'" he said, gesturing toward a computer display of genes.

"Imagine you wanted to write a book as an author, but you couldn't use the word 'the.' It would be as difficult to look through all of your DNA and try to find a gene that didn't have at least one patent on it," Mason said.

By one estimate, more than 3,500 patents are held on naturally occurring gene sequences by pharmaceutical giants like Amgen, Genentech and GlaxoSmithKline.

Bio, the Biotechnology Industry Organization, called Thursday's court's ruling "a troubling departure" that "could create business uncertainty."

Christopher Mason is a geneticist at Weill Cornell Medical College.
Christopher Mason is a geneticist at Weill Cornell Medical College. CBS News

But the American Medical Association called it a "clear victory for patients."

"We should not hold hostage the best medical care just so someone can make a profit. We value lives more than we value profit," Mason said.

After falling sharply Wednesday, most biotech stocks actually rallied Thursday, in part because the ruling still protects patents on synthetic or artificial DNA, a big profit center for many biotech companies.

  • Anthony Mason
    Anthony Mason

    CBS News senior business and economics correspondent; Co-host, "CBS This Morning: Saturday"